Case Study: a top-50 pharmaceutical partner rescues a stalled IgG program with Cradle, delivering 10 candidates meeting potency and developability criteria

Top-50 Pharmaceutical Partner rescues stalled IgG campaign with Cradle, delivering 10 candidates in 3 rounds

A top-50 pharmaceutical company faced a major challenge in developing a therapeutic IgG, as their prior screening and optimization efforts had failed to produce a single candidate that met both the required potency and the six critical developability criteria. Their program was stalled, with a parental sequence that had unfavorable manufacturability characteristics and two specific sequence liabilities that needed to be eliminated. They engaged Cradle to rescue the project.

Using its machine learning optimization framework, Cradle implemented a multi-property approach over three rounds of design. The solution successfully generated 10 candidates that all met the strict potency window and all six developability metrics, including improved aggregation and reduced immunogenicity. For the customer, Cradle's solution rescued a stalled program from termination, allowing 10 variants to advance to the next pipeline stage and preserving their substantial prior investment.